Dienogest

Structural formula
General
Non-proprietary name	Dienogest
other names	17 α- Hydroxy-3-oxo-19 β -norpregna-4,9-diene-21-nitrile
Molecular formula	C 20 H 25 NO 2
External identifiers / databases
EC number	639-448-2
ECHA InfoCard	100.167.087
PubChem	68861
ChemSpider	62093
DrugBank	DB09123
Wikidata	Q139160
Drug information
ATC code	G03 AA17 ; G03 FA15 ;
Drug class	Progestins
properties
Molar mass	311.42 g · mol -1
Physical state	firmly
Melting point	209-214 ° C
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances danger
H and P phrases	H: 351-360-362
	P: ?
Toxicological data	4000 mg kg −1 ( LD 50 , mouse , oral )
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Dienogest is a synthetic progestin that as a hormonal contraceptive for contraception and for the treatment of menstrual problems, acne and endometriosis is used in women.

Dienogest has an antiandrogenic effect and is therefore one of the receptor blockers. Dienogest comprises a single 19-Norge days no estrogenic , anti-estrogenic or androgenic in partial action.

history

Dienogest was first synthesized in 1979 as STS 557 in Jena. It showed 10 times the potency compared to levonorgestrel . 1995 was micro pill Valette ^® of Jena Pharm launched. In May 2010, Visanne, the first monopreparation for the indication of endometriosis, was introduced.

Trade names

Monopreparations

Visanne 2 mg (D, A, CH), Metrissa 2 mg (D, A), Zafrilla (D, A), Dinuve (D), Verybel (D), Diemono (D, A), Endovelle (A), Aridya (A)

Combination preparations

Aristelle (D), Climodien (D), Lafamme (D), Larissa Gynial (A), Motion (A), Qlaira (D, A, CH), Valette (D, A, CH), Maxim (D), Velafee (D), Dienovel (D)

Individual evidence

↑ ^a ^b entry on Dienogest. In: Römpp Online . Georg Thieme Verlag, accessed on June 19, 2014.
↑ Template: CL Inventory / not harmonized There is not yet a harmonized classification for this substance . A labeling of 17-alpha-cyanomethyl-17-beta-hydroxy-estra-4,9 (10) -dien-3-one in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA) is reproduced, which is derived from a self-classification by the distributor on January 14, 2020.
↑ Entry on Dienogest in the ChemIDplus database of the United States National Library of Medicine (NLM), accessed on January 14, 2020.
↑ Oettel, M. & Kurischko, A. (1980): STS 557, a new orally active progestin with antiprogestational and contragestational properties in rabbits. In: Contraception. 21 (1): 61-69. PMID 7357870 doi: 10.1016 / 0010-7824 (80) 90140-7 .
↑ GESTAGEN DIENOGEST (VISANNE) IN ENDOMETRIOSIS. Retrieved May 1, 2020 .

[Römpp-1] try on Dienogest. In: Römpp Online . Georg Thieme Verlag, accessed on June 19, 2014.

[2] Template: CL Inventory / not harmonized There is not yet a harmonized classification for this substance . A labeling of 17-alpha-cyanomethyl-17-beta-hydroxy-estra-4,9 (10) -dien-3-one in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA) is reproduced, which is derived from a self-classification by the distributor on January 14, 2020.

[ChemIDplus-3] Entry on Dienogest in the ChemIDplus database of the United States National Library of Medicine (NLM), accessed on January 14, 2020.

[4] Oettel, M. & Kurischko, A. (1980): STS 557, a new orally active progestin with antiprogestational and contragestational properties in rabbits. In: Contraception. 21 (1): 61-69. PMID 7357870 doi: 10.1016 / 0010-7824 (80) 90140-7 .

[5] GESTAGEN DIENOGEST (VISANNE) IN ENDOMETRIOSIS. Retrieved May 1, 2020 .